Penumbra (NYSE:PEN) Stock Price Breaks Below 50-Day Moving Average - Here's What Happened

Penumbra logo with Healthcare background
Image from MarketBeat Media, LLC.

Key Points

  • Penumbra shares fell below their 50-day moving average of $320.15, trading as low as $319.05 and last at about $319.43.
  • Analyst sentiment is mostly neutral: 14 analysts rate the stock Hold and three rate it Buy, with a consensus price target of $367.07.
  • In its latest quarter, Penumbra missed earnings estimates ($1.07 per share versus $1.20 expected) but beat revenue expectations, with sales up 15.6% year over year.
  • MarketBeat previews the top five stocks to own by December 1st.

Shares of Penumbra, Inc. (NYSE:PEN - Get Free Report) passed below its 50-day moving average during trading on Tuesday. The stock has a 50-day moving average of $320.15 and traded as low as $319.05. Penumbra shares last traded at $319.4290, with a volume of 365,983 shares changing hands.

Wall Street Analyst Weigh In

A number of research firms have recently weighed in on PEN. Weiss Ratings raised shares of Penumbra from a "hold (c)" rating to a "hold (c+)" rating in a research report on Friday, October 30th. Zacks Research raised shares of Penumbra from a "strong sell" rating to a "hold" rating in a research report on Monday, August 24th. Finally, Canaccord Genuity Group reissued a "hold" rating and set a $374.00 price target on shares of Penumbra in a research report on Tuesday. Three equities research analysts have rated the stock with a Buy rating and fourteen have given a Hold rating to the company's stock. Based on data from MarketBeat, the company currently has an average rating of "Hold" and a consensus price target of $367.07.

View Our Latest Stock Analysis on Penumbra

Penumbra Stock Performance

The firm has a market capitalization of $12.59 billion, a PE ratio of 80.46 and a beta of 0.71. The company has a current ratio of 5.89, a quick ratio of 3.92 and a debt-to-equity ratio of 0.01. The business's 50 day simple moving average is $320.15 and its two-hundred day simple moving average is $325.71.

Penumbra (NYSE:PEN - Get Free Report) last released its quarterly earnings results on Thursday, October 29th. The company reported $1.07 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $1.20 by ($0.13). Penumbra had a return on equity of 10.39% and a net margin of 10.06%. The firm had revenue of $410.15 million during the quarter, compared to analysts' expectations of $401.41 million. During the same quarter last year, the business earned $0.97 earnings per share. The business's quarterly revenue was up 15.6% on a year-over-year basis. Research analysts expect that Penumbra, Inc. will post 4.96 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Institutional investors have recently bought and sold shares of the company. Mitsubishi UFJ Asset Management Co. Ltd. bought a new position in shares of Penumbra in the second quarter worth approximately $25,000. Keating Financial Advisory Services Inc. purchased a new stake in shares of Penumbra in the second quarter worth $31,000. MassMutual Private Wealth & Trust FSB increased its stake in shares of Penumbra by 48.7% in the third quarter. MassMutual Private Wealth & Trust FSB now owns 116 shares of the company's stock worth $37,000 after purchasing an additional 38 shares in the last quarter. CoreCap Advisors LLC raised its position in shares of Penumbra by 1,066.7% during the 3rd quarter. CoreCap Advisors LLC now owns 140 shares of the company's stock valued at $45,000 after purchasing an additional 128 shares during the period. Finally, Northwestern Mutual Wealth Management Co. bought a new stake in shares of Penumbra during the 2nd quarter valued at $51,000. Institutional investors own 88.88% of the company's stock.

About Penumbra

(Get Free Report)

Penumbra, Inc. is a medical technology company that develops and markets devices for treating vascular conditions. Its products are used in neurovascular procedures, including the treatment of ischemic stroke and aneurysms, and in peripheral vascular procedures involving conditions such as pulmonary embolism and deep vein thrombosis. The company's offerings include aspiration and mechanical thrombectomy systems, embolization coils, and related catheter-based devices. Penumbra was founded in 2004 and is headquartered in Alameda, California.

Featured Stories

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in Penumbra Right Now?

Before you consider Penumbra, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Penumbra wasn't on the list.

While Penumbra currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

The Infrastructure's Backbone: 10 Stocks Powering the AI Buildout Cover

The AI boom extends far beyond the biggest tech names. Discover 10 companies supplying the memory, storage, networking, semiconductor manufacturing, and power infrastructure that make AI possible. Learn where the next wave of AI investment opportunities may emerge—and the key risks investors should watch as the global AI buildout accelerates.

Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines